Related Experiment Videos
[Is immunosuppression a future therapeutic strategy for multiple sclerosis?]
1Clinique neurologique centre hospitalier universitaire de Rennes, hôpital de Pontchaillou, France.
Pathologie-Biologie
|May 18, 2000
Summary
This study reviews multiple sclerosis treatments, highlighting the partial efficacy of immunosuppressors like mitoxantrone and immunomodulators such as beta-interferons and glatiramer acetate in managing MS symptoms and progression.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Previous studies showed limited efficacy for azathioprine, cyclophosphamide, and methotrexate in multiple sclerosis (MS).
- Recent clinical trials indicate partial efficacy of immunosuppressive and immunomodulatory agents in MS, but their precise role in disease modification remains unclear.
Purpose of the Study:
- To evaluate the efficacy of various immunosuppressive and immunomodulatory agents in treating multiple sclerosis.
- To discuss the current understanding of how these agents modify the natural course of MS.
Main Methods:
- Review of recent clinical trials and European controlled trials.
- Analysis of data on clinical outcomes and magnetic resonance imaging (MRI) criteria.
Main Results:
- Mitoxantrone demonstrated efficacy in clinical and MRI criteria for MS, but its use is limited by cardiotoxicity.
- Beta-interferons (1a/1b) and glatiramer acetate showed a 30% reduction in relapse frequency and disability progression.
- Immunomodulatory agents are well-tolerated for early, long-term MS treatment.
Conclusions:
- Mitoxantrone is effective but reserved for severe cases due to toxicity.
- Beta-interferons and glatiramer acetate offer viable immunomodulatory treatment options for MS.
- Future strategies may involve early intervention with immunomodulators and combination therapies.